Completed PHASE1 INTERVENTIONAL 4-arm NCT00429806

DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy

DHEA Bioavailability Following Administration of Vaginal Suppositories in Post-Menopausal Women With Vaginal Atrophy-Phase I Randomized,Placebo-Controlled, Double-Blind Study.

Sponsor: CHU de Quebec-Universite Laval

Conditions Vaginal Atrophy

Interventions DHEA Placebo

Updated 7 times since 2017 Last updated: Apr 6, 2017 Started: Nov 30, 2006 Primary completion: Mar 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00429806, this PHASE1 trial focuses on Vaginal Atrophy and remains completed. Sponsored by CHU de Quebec-Universite Laval, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Jul 2017 [monthly]

Completed PHASE1

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CHU de Quebec-Universite Laval

Data source: CHU de Quebec-Universite Laval

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Québec, Canada